Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease.

For CSF pTau181, a nominally significant median change from baseline of −19.6 %, ( p = 0.049, Fig. 2 and Supplemental Tables 6 and 7) was measured in the 60 mg/kg Q4W sabirnetug-treated participants versus the placebo-treated participants, which showed an increase.

also in 4,806 other papers